The Ordinary
The Ordinary sells lab-grade actives for under $20, and that alone turned the entire skincare industry into a before-and-after photo.
The Ordinary launched in 2016 under Toronto-based parent company DECIEM, and it did something the beauty industry had successfully avoided for decades: it told you exactly what was in the bottle and charged you almost nothing for it. No fantasy marketing, no celebrity faces, just retinol, niacinamide, and acids named like chemistry homework. The transparency was radical, and it worked.
The brand exploded into a cult phenomenon because it democratized the kind of ingredient-led skincare that used to require a dermatologist’s budget. A 30ml bottle of their Buffet serum runs around $14. A comparable “luxury” peptide serum from a prestige brand can cost 10–15× more. Shoppers noticed.
But behind the minimalist branding sits a genuinely turbulent corporate history. DECIEM’s co-founder Brandon Truaxe made international headlines not for the products, but for a public breakdown that played out in real time on Instagram, and his death in 2019 cast a long shadow over the company’s otherwise triumphant rise.
Ownership has since stabilized. The Estée Lauder Companies, which began investing in DECIEM in 2017, took majority control in 2021 and acquired the remainder of the business in 2023, valuing DECIEM at approximately $2.2 billion. The Ordinary is now very much part of the prestige beauty establishment it once disrupted.
People keep searching for The Ordinary because the questions never really stopped: Is it safe? Is it too cheap to trust? Does it actually work? And increasingly, given its parent company’s broader business practices, should I be buying it at all? This page answers all of that, straight.